Early Intensive Antiretroviral Therapy in Infants With HIV to Explore Remission Outcomes
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-09-09
1120
Participants Needed
47
Research Sites
204 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of early intensive antiretroviral therapy ART with or without broadly neutralizing antibodies on achieving HIV remission in infants living with HIV. This phase III study includes two groups infants born to mothers with limited or no antiretroviral use during pregnancy and infants diagnosed with HIV within 48 hours of birth who start ART immediately. The goal is to see if early treatment can suppress HIV to undetectable levels.
Participants will receive one of seven intensive ART regimens combining nucleoside reverse transcriptase inhibitors NRTIs with drugs like nevirapine, lopinavirritonavir, raltegravir, dolutegravir, and monoclonal antibodies VRC01 or VRC07-523LS. Therapy begins within 48 hours of birth and may include switches in medication based on age and weight. The study has four steps initial evaluation and therapy start, up to 192 weeks of treatment with monitoring, possible treatment interruption for those with sustained viral suppression, and re-initiation of ART if viral rebound occurs.
During the study, infants undergo regular HIV testing, safety monitoring, and immune assessments. Researchers track how many achieve HIV remission by week 48 and monitor viral suppression and adverse events through week 192. If treatment interruption is attempted, participants are closely observed for viral rebound for up to ten years, followed by monitoring after ART re-initiation until age five or six months after viral suppression. The entire study may last several years to evaluate long-term outcomes.
CONDITIONS
Brief Title
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
Research Team
A
Anne Coletti, MS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborating Sponsor
How This Trial Compares With Other Options
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Very Early Intensive ART
Guideline-Recommended Early ART
What it is
Combination antiretroviral regimens, sometimes including monoclonal antibodies (VRC01 or VRC07-523LS), started within 48 hours of birth in HIV-infected neonates. Regimens and switches varied by cohort and study step, with initial treatment typically including 2 NRTIs plus nevirapine and lopinavir/ritonavir or raltegravir, and escalation or switch to dolutegravir-based or antibody-containing regimens.
Standard-of-care antiretroviral therapy as recommended by current guidelines, usually 2 NRTIs plus nevirapine and/or protease inhibitor or integrase inhibitor, started as soon as possible after birth for HIV-infected neonates. Monoclonal antibodies and investigational intensification are not routine components.
Role in the study or care
Primary intervention tested in each trial cohort/step; all eligible infants received an assigned investigational ART regimen with or without monoclonal antibody.
Represents the standard-of-care therapy given to neonates with newly diagnosed HIV infection in clinical practice outside this research study.
Primary use or goal
Evaluate whether immediate, intensive ART regimens started within the first 48 hours of life (with/without monoclonal antibodies) can achieve HIV remission or allow treatment interruption in infants with confirmed in utero HIV infection.
Provide prompt viral suppression, support immune development, and prevent disease progression in infants with HIV diagnosed soon after birth. Cure or remission without lifelong ART is not expected in routine care.
How it is given or performed
ART regimen started within 48 hours of birth, dosed according to infant age and weight, with possible switches/augmentation based on trial-defined steps. Selected regimens in some cohorts include subcutaneous monoclonal antibody injections.
ART initiated as soon as diagnosis is confirmed, using WHO- or national guideline-recommended drugs, dosed by weight and age; monoclonal antibody therapy is not routinely included.
Evidence status / maturity
Ongoing clinical investigation. Evidence for very early intensive ART, especially with monoclonal antibodies and treatment interruption, is limited to phase 1/2 clinical studies; results for HIV remission and long-term ART-free survival are not yet established.
Extensive clinical evidence supports prompt standard ART initiation in neonates for viral suppression, improved survival, and prevention of HIV-related disease progression, but not for ART-free remission.
Important limitations
Long-term outcomes, including sustained HIV remission and safe treatment interruption, are uncertain. Risk of drug toxicity, complexity of regimen, laboratory monitoring needs, and access to investigational monoclonal antibodies may limit generalizability. Not all infants may be eligible for later study phases, especially those failing viral suppression.
Requires lifelong daily ART adherence and monitoring; cure or ART-free remission are not anticipated with standard regimens. Potential for treatment-related toxicity exists, but regimens are well-studied and supported by extensive safety data.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 0 - 48Hours
All Genders
Eligibility Criteria
You may qualify if you...
Mothers with presumed or confirmed HIV infection who can provide informed consent
Mothers not previously enrolled in this study with another infant
Mothers who did not receive antiretroviral therapy during the current pregnancy
Infants less than or equal to 48 hours old
Infants born at or after 37 weeks gestation
Infants weighing at least 2 kilograms at birth
Infants able to take antiretroviral medications by mouth or feeding tube
Infants with no other significant diseases interfering with study participation
Infants whose mothers meet inclusion criteria
Infants with confirmed in utero HIV infection for Step 2 enrollment
Infants meeting viral suppression and immune criteria for Step 3 eligibility
Infants meeting viral rebound or clinical criteria for Step 4 enrollment
You will not qualify if you...
Mothers previously enrolled in this study with another infant
Mothers who received antiretroviral therapy during the current pregnancy
Infants with clinically significant diseases other than HIV that interfere with participation
Infants unable to take antiretroviral medications by mouth or feeding tube
Infants not meeting viral suppression criteria required for treatment interruption
Infants breastfed with recent exposure to breast milk less than six weeks prior to testing for Step 3
Infants with confirmed plasma HIV RNA �3e= 200 copies/mL during specified testing periods
Infants assessed by investigators as unable to adhere to study schedules or procedures
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Initial enrollment and HIV infection evaluation within 48 hours of birth
Intensive Treatment
Duration - Up to 192 weeks
Infants receive one of several early intensive ART regimens starting within 48 hours of birth and followed for up to 192 weeks. Viral suppression is monitored regularly.
Regular visits for medication administration and viral load testing
Treatment Interruption and Monitoring
Duration - Up to 10 years
Eligible infants with sustained viral suppression may stop ART under close monitoring for viral rebound for up to ten years.
Frequent monitoring visits to detect viral rebound
ART Re-initiation and Follow-up
Duration - Until age 5 years or 6 months after viral suppression
Infants who experience viral rebound or meet clinical criteria will restart ART and be monitored until viral suppression is regained, continuing until age five or six months after suppression.
Regular follow-up visits for treatment and monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
9
Similar Trials
Improving HIV Testing in European Hospitals by Introducing Dedicated HIV Teams A Multicenter Study Across Ten Countries
Study of Cardiovascular Risk in Children and Young Adults With Chronic Health Conditions
Evaluating Codivir with Standard Antiretroviral Therapy for Treatment-Naive Adults with HIV Infection
Randomized Trial of Colchicine to Reduce Coronary Artery Inflammation in People 50 and Older Living With HIV and High Cardiovascular Risk
Donation of Blood and Tissue Samples for Research on HIVAIDS-Related Cancers in Adults
Retrospective Study on Dental Care Needs for Adults Living With HIV in Pays de la Loire Using COREVIH Data
Comparison of DarunavirCobicistat Plus Lamivudine Versus DarunavirCobicistat Plus Tenofovir AlafenamideEmtricitabine
for Virologically Suppressed Adult Men With HIV
Evaluating Effectiveness and Safety at 24 and 48 Weeks
Comparing DarunavirCobicistat Plus Lamivudine to DarunavirCobicistat Plus TenofovirEmtricitabine
for Men with Controlled HIV-1 Infection in Mexico 48-Week Safety and Effectiveness Study
HOPE in Action Study on Liver Transplantation from Donors with HIV to HIV-Positive Recipients
Assessing Infection, Cancer, and Long-Term Outcomes
Study of Heart Transplant Outcomes in HIV-Positive Adults Receiving Hearts from HIV-Positive or HIV-Negative Donors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study.
ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept study.
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.
Theodore D Ruel, Edmund V Capparelli, Camlin Tierney...